DCMIC
TERN

Decheng Capital Management III (Cayman)’s Terns Pharmaceuticals TERN Stock Holding History

Decheng Capital Management III (Cayman)’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$3.59M Hold
714,285
– – 1.2% 18
2023
Q2 		$6.25M Hold
714,285
– – 1.96% 12
2023
Q1 		$8.46M Hold
714,285
– – 3.41% 11
2022
Q4 		$7.27M Hold
714,285
– – 2.72% 12
2022
Q3 		$4.21M Hold
714,285
– – 1.53% 17
2022
Q2 		$1.77M Hold
714,285
– – 0.67% 19
2022
Q1 		$2.12M Buy
+714,285
New +$3.05M 0.65% 20

Other funds holding TERN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Decheng Capital Management III (Cayman)'s TERN Position: Q3 2023 in Review

Decheng Capital Management III (Cayman) held its Terns Pharmaceuticals (TERN) position steady in Q3 2023 at 714,285 shares worth $3.59M. The position accounts for 1.2% of the portfolio, ranked #18.

Decheng Capital Management III (Cayman) first reported a position in TERN in Q1 2022 and has held it in 7 quarters since. The position peaked at $8.46M in Q1 2023. 93 funds tracked by Wall St. Rank hold TERN as of Q3 2023.

  • Decheng Capital Management III (Cayman) held 714,285 shares of Terns Pharmaceuticals worth $3.59M as of Q3 2023.
  • Decheng Capital Management III (Cayman) left its Terns Pharmaceuticals share count unchanged in Q3 2023.
  • Terns Pharmaceuticals made up 1.2% of Decheng Capital Management III (Cayman)'s portfolio in Q3 2023, its #18 holding.
  • Decheng Capital Management III (Cayman) first reported a position in Terns Pharmaceuticals in Q1 2022 and has held it in 7 quarters since.
  • Decheng Capital Management III (Cayman)'s Terns Pharmaceuticals position peaked at $8.46M in Q1 2023.
  • 93 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q3 2023.

Based on Decheng Capital Management III (Cayman)'s 13F filing for Q3 2023, filed 13 Nov 2023.